1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

09 May 2024
Admin
News Article

BioVersys Expands Collaboration with GSK

BioVersys Expands Collaboration with GSK and Boosts Series C Funding by CHF 12.3 Million

Overview

BioVersys AG, a clinical-stage biopharmaceutical company, and GSK plc (LSE/NYSE: GSK), a global biopharma leader, have announced an expansion of their strategic collaboration to accelerate the clinical development of alpibectir (BVL-GSK098) for tuberculosis (TB) treatment.

Alpibectir

Alpibectir, a novel small molecule developed through a successful public-private partnership involving GSK, Pasteur Institute Lille, and the University of Lille, is currently undergoing evaluation in a Phase 2a proof-of-concept study in pulmonary TB patients in South Africa.
This compound, in combination with ethionamide (Eto), introduces a fresh approach to overcoming resistance and enhancing the effectiveness of existing antibiotics.

Extension in Collaboration

The collaboration between GSK and BioVersys will extend beyond the current Phase 2a study to develop alpibectir for both pulmonary TB and TB meningitis programs, aiming to make the treatment available to patients expeditiously.
Investment:- In addition to their collaboration, GSK will make an equity investment in BioVersys’ latest funding round, enhancing the Series C financing by CHF 12.3 million, totaling proceeds of CHF 44.9 million for the Series C round to date. These funds will support the clinical development of BioVersys’ portfolio, including BV100, a potential breakthrough antibiotic targeting Acinetobacter baumannii.

BioVersys on The Collab

• BioVersys, expressed enthusiasm about the expanded collaboration with GSK and the progress in alpibectir's development.
• He emphasized the urgency in addressing TB, a global health threat with inadequate treatment options.

GSK on Potential of Alpibectir

GSK, highlighted the commitment to combatting TB and the potential of alpibectir to diversify treatment options. He emphasized the importance of partnerships in addressing global health challenges effectively.

About TB

TB, caused by Mycobacterium tuberculosis, remains a significant global health concern, with millions of new cases and deaths annually, and a rising incidence of drug-resistant strains.
The collaboration between BioVersys and GSK represents a concerted effort to address this pressing public health issue.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!